Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07680790 · ClinicalTrials.gov registry record · Phase 3

Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based Chemotherapy for EGFRmt Non-small Cell Lung Cancer (IZABRIGHT-Lung02)

A Phase 3 study, sponsored by Bristol-Myers Squibb.

Not yet
Registry status
Phase 3
Development phase
850
Enrollment target

NCT07680790: Clinical Trial Phase 3 study, sponsored by Bristol-Myers Squibb.

NCT07680790 is a Phase 3 study that has not yet begun recruiting, run by Bristol-Myers Squibb. The registered enrollment target is 850 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (10% higher). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07680790, a Phase 3 study, has not yet begun recruiting, sponsored by Bristol-Myers Squibb.

NOT YET RECRUITING
Registry status
Phase 3
Development phase
850 participants
Enrollment target

Study Summary

The purpose of this study is to evaluate izalontamab brengitecan (iza-bren) combined with osimertinib in participants with previously untreated, locally advanced or metastatic EGFR-mutant NSCLC, compared to osimertinib alone or osimertinib combined with platinum-based chemotherapy

Interventions

  • DRUG Carboplatin
  • DRUG Cisplatin
  • DRUG Osimertinib
  • DRUG Pemetrexed
  • DRUG Iza-bren

Trial Details

FieldValue
Enrollment Target 850 participants
Start Date 2026-09-30
Est. Completion 2031-12-30
Phase Phase 3
Bristol-Myers Squibb

1,025 total trials

What is known before NCT07680790 opens enrollment

NCT07680790 is an interventional study that assigns participants to a tested intervention. The registered 850 participants enrollment target is mid-sized for trials with a published cap, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (10% higher).

The record links to 0 conditions, and to 5 interventions - of which Carboplatin is the first listed.

NCT07680790 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT07680790 about?

NCT07680790 is a clinical study titled "Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based Chemotherapy for EGFRmt Non-small Cell Lung Cancer (IZABRIGHT-Lung02)". The purpose of this study is to evaluate izalontamab brengitecan (iza-bren) combined with osimertinib in participants with previously untreated, locally advanced or metastatic EGFR-mutant NSCLC, compared to osimertinib alone or osimertinib combined with platinum-based chemotherapy

What is the current status of trial NCT07680790?

This trial is currently not yet recruiting. It is a Phase 3 study. The enrollment target is 850 participants. The study started on 2026-09-30. Estimated completion is 2031-12-30.

What interventions are being tested in trial NCT07680790?

The interventions under investigation include: Carboplatin (DRUG), Cisplatin (DRUG), Osimertinib (DRUG), Pemetrexed (DRUG), Iza-bren (DRUG).

Who is sponsoring clinical trial NCT07680790?

This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.

Learn More About Clinical Trials

How this trial's enrollment target compares

Where NCT07680790's enrollment target sits among peer trials

850 387th of 2000 higher than 1,612 of 2,000 other Phase 3 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03507257 · 850 participants

    Longitudinal Early-onset Alzheimer's Disease Study Protocol

  • NCT05846841 · 850 participants · NA

    Personalized Tobacco Treatment in Primary Care (MOTIVATE)

  • NCT05987059 · 850 participants · Phase 2

    Involving Communities in Addressing the Maternal Health Crisis: Making an IMPACT

  • NCT06289673 · 850 participants · Phase 4

    Identification of Necessary Information for Treatment Induction in Newly Diagnosed Acute Lymphoblastic Leukemia/Lymphoma

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT07680790, the US trial registry maintained by the National Library of Medicine. NCT07680790 (mid enrollment · none site footprint · not yet recruiting) retrieved and formatted by PlainTrial, see methodology.